Vol.

No.

June 03, 2022Jun 03, 2022

DOWNLOAD THE PDF

Cover Story

#MyFirstASCO: Memories from 57 years of annual meetings

By Alexandria Carolan and Katie Goldberg

The ASCO annual meeting began in 1964 as a group of 51 physicians finalizing the bylaws of the organization—and has since turned into a much-anticipated global event that brings together 35,000 to 40,000 people across all areas of oncology.

Conversation with The Cancer Letter

ATOM Coalition sees patent sharing as key to overcoming scarcity of cancer drugs in LLMICs

By Alice Tracey

Cancer History Project Conversation with The Cancer Letter Free

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

By Deborah Doroshow and Alexandria Carolan

Free In the Archives

ASCO annual meetings through the years: A timeline of The Cancer Letter’s coverage

In Brief

Emory Winship receives $11M NCI grant to improve immunotherapy for lung cancer

Sylvester begins construction of Transformational Cancer Research Building

Cancer care equity legislation passes CA senate vote

Reena Philip named associate director of biomarkers and precision oncology at OCE

Mona Fouad receives 2022 Vilcek-Gold Award for Humanism in Healthcare

Chris Neumann named VP of learning and education, Kirsta Suggs named DEI director at ASTRO

ASTRO submits comments to CMS following April 2022 proposed rule to indefinitely delay RO Model

Clinical Roundup

NYU study: Exercise amplifies immune attack on pancreatic cancer

JHU study: Age-related lung changes provide pathway for metastatic growth of dormant melanoma cells

VCU Massey study: Protein-based combination therapy overcomes tumor resistance to colorectal cancer treatment

Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

ACS study: Children with parental cancer have increased unmet economic needs in food, housing, and transportation

ACS study: Race and ethnicity, cancer type affect mortality risk from CVD in cancer survivors

Adjuvant everolimus may improve RFS in high-risk kidney cancer

Glofitamab induces CR in patients with r/r DLBCL

Allocetra + PD-1 checkpoint inhibition shows survival benefit in ovarian cancer

CLN-081 demonstrates positive potential in EGFR exon 20 insertion mutation positive NSCLC

Sugemalimab, aumolertinib show clinical benefit in NSCLC, r/r ENKTL

Genetic testing changes cancer treatment plans, Invitae studies suggest

CPI-613 may be used to treat clear cell sarcoma, pancreatic, biliary tract cancer

Lasofoxifene + abemaciclib shows potential in ER+/HER2− breast cancer with ESR1 mutation

Drugs & Targets

FDA approves two Opdivo-based regimens in unresectable advanced or metastatic ESCC

FDA approves Kymriah in relapsed or refractory follicular lymphoma

FDA grants priority review to Omblastys in pediatric CNS/leptomeningeal metastasis from neuroblastoma

FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC

OncoHealth, Blue Note Therapeutics partner to provide a digital therapeutic for cancer-related anxiety and depression

C2i Genomics, Karkinos Healthcare partner to bring AI-powered cancer R&D to India

Ultima Genomics to provide low-cost $100 genome sequencing

NCI Trials

NCI Trials for June 2022

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues